Nanocapsular formulation of active pharmaceutical ingredients
Aplication No: WO2015189387A1
Aplication No: EP2932965 B1
Nanocapsules of protamine
Aplication No: US9642816B2
Nanocapsules with a polymer shell
Aplication No: EP2664324 B1
Nanocápsules with a polymeric cover
Aplication No: P201130015
Nanoparticles of chitosan and polyethyleneglycol as a system for the administration of biologically-active molecules
Aplication No: WO2006097558A3
Nanoparticles of polyoxyethylenated derivatives
Aplication No: WO2005002550A1
Nanoparticles with protected interiors and methods of use thereof
Aplication No: US10,471,020 B2
Nanopartículas con interiores protegidos, y métodos de uso de las mismas
Aplication No: P201631221
Nanoparticulate systems prepared from sorbitan esters
Aplication No: WO2012ES70774 20121108
Nanosistemas con complejos
Aplication No: P201830729
Novel biphenylsulfoximines as allosteric modulators of the dopamine D1 receptor
Aplication No: EP17382372.5
Nuevos derivados de piperidina y piperazina. Procedimiento para la preparación y aplicación de 4-sustituido piperidinialquil y 4-sustituido piperazinoalquil heterocicloalcanonas.
Aplication No: P9601012
Organoid culture system and method for sterilizing and organoid culture system
Aplication No: WO/2020/049206
Partículas purificadas de polen y su uso para administrar nanosistemas
Aplication No: P201730151
Partículas purificadas de polen y su uso para administrar nanosistemas
Aplication No: ES2613585 B2
Partículas purificadas de polen, procedimiento y su uso para administrar nanosistemas
Aplication No: P201730152
Pharmaceutical composition for its use in the treatment of inflammatory diseases
Aplication No: P202031238
Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of dyskinesias induced by L-DOPA (licensed to WOOLSEY PHARMACEUTICALS, INC, New York, USA. July 6th, 2021)
Aplication No: PCT/ES2020/070482
Phosphodiesterase-7-inhibiting heterocyclic derivatives
Aplication No: WO2012150369